<span item_type="fundamental" item_id="de6d80eb11132fce8c432837a25b5490" counter_id="ST/US/MNMD" env="prod"></span><span item_type="announcement" item_id="544372410965624065" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -0.5.</p><p></p><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: - $42.7 million for the three months ended June 30, 2025, compared to - $5.9 million for the same period in 2024. - $66.1 million for the six months ended June 30, 2025, compared to - $60.3 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100925/mnmd-20250630.htm"></span></li><li><strong>Research and Development Expenses</strong>: $29.8 million for the three months ended June 30, 2025, compared to $14.6 million for the same period in 2024. $53.2 million for the six months ended June 30, 2025, compared to $26.4 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100925/mnmd-20250630.htm"></span></li><li><strong>General and Administrative Expenses</strong>: $11.1 million for the three months ended June 30, 2025, compared to $9.8 million for the same period in 2024. $19.9 million for the six months ended June 30, 2025, compared to $20.3 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100925/mnmd-20250630.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: - $59.0 million for the six months ended June 30, 2025, compared to - $36.6 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100925/mnmd-20250630.htm"></span></li><li><strong>Net Cash Used in Investing Activities</strong>: - $202.0 million for the six months ended June 30, 2025, compared to $0 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100925/mnmd-20250630.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: $20.7 million for the six months ended June 30, 2025, compared to $180.0 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100925/mnmd-20250630.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Accumulated Deficit</strong>: - $465.0 million as of June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100925/mnmd-20250630.htm"></span></li><li><strong>Cash, Cash Equivalents, and Investments</strong>: $237.9 million as of June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100925/mnmd-20250630.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><h4>Core Business Focus</h4><ul><li><p><strong>MM120 Program</strong>: Advancing MM120 into Phase 3 clinical trials for generalized anxiety disorder (GAD) and major depressive disorder (MDD). Expected topline readouts in 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100925/mnmd-20250630.htm"></span></p></li><li><p><strong>MM402 Program</strong>: Developing MM402 for autism spectrum disorder (ASD). Further trials expected, with timing and scope to be determined.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100925/mnmd-20250630.htm"></span></p><h4>Non-Core Business</h4></li><li><p><strong>Exploratory Programs</strong>: Exploring additional programs through external collaborations to expand the drug development pipeline and broaden potential applications of lead product candidates.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100925/mnmd-20250630.htm"></span></p><h4>Priority</h4></li><li><p><strong>Funding</strong>: Believes cash, cash equivalents, and investments will be sufficient to fund operations into 2027 and at least 12 months beyond the first Phase 3 topline data readout for MM120 in GAD.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100925/mnmd-20250630.htm"></span></p></li></ul>

Mind Medicine MindMed | 10-Q: FY2025 Q2 EPS: USD -0.5